Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.

MLA

McDermott, David F., et al. “Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 39, no. 9, Mar. 2021, pp. 1029–39. EBSCOhost, https://doi.org/10.1200/JCO.20.02365.

APA

McDermott, D. F., Lee, J.-L., Ziobro, M., Suarez, C., Langiewicz, P., Matveev, V. B., Wiechno, P., Gafanov, R. A., Tomczak, P., Pouliot, F., Donskov, F., Alekseev, B. Y., Shin, S. J., Bjarnason, G. A., Castellano, D., Silverman, R. K., Perini, R. F., Schloss, C., & Atkins, M. B. (2021). Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 39(9), 1029–1039. https://doi.org/10.1200/JCO.20.02365

Chicago

McDermott, David F, Jae-Lyun Lee, Marek Ziobro, Cristina Suarez, Przemyslaw Langiewicz, Vsevolod Borisovich Matveev, Pawel Wiechno, et al. 2021. “Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 39 (9): 1029–39. doi:10.1200/JCO.20.02365.